US5075109A
(en)
*
|
1986-10-24 |
1991-12-24 |
Southern Research Institute |
Method of potentiating an immune response
|
US5811128A
(en)
*
|
1986-10-24 |
1998-09-22 |
Southern Research Institute |
Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
|
GR1000047B
(el)
*
|
1988-02-04 |
1990-05-11 |
Clinical Technologies Ass |
Συστηματα χορηγησης φαρμακολογικων παραγοντων.
|
US5023080A
(en)
*
|
1988-06-17 |
1991-06-11 |
Basic Bio Systems, Inc. |
Time release protein
|
US4925677A
(en)
*
|
1988-08-31 |
1990-05-15 |
Theratech, Inc. |
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
|
US5041292A
(en)
*
|
1988-08-31 |
1991-08-20 |
Theratech, Inc. |
Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
|
CA2018064C
(en)
*
|
1989-06-08 |
1996-04-16 |
Kaspar Saner |
Force transducer and method of producing it
|
CA2071867A1
(en)
*
|
1989-11-06 |
1991-05-07 |
Edith Mathiowitz |
Method for producing protein microspheres
|
DE69133120T2
(de)
|
1990-07-17 |
2003-05-15 |
Univ Oklahoma Norman Board Of |
GMP-140 Ligand
|
US6099856A
(en)
*
|
1992-06-15 |
2000-08-08 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5541155A
(en)
*
|
1994-04-22 |
1996-07-30 |
Emisphere Technologies, Inc. |
Acids and acid salts and their use in delivery systems
|
US5693338A
(en)
*
|
1994-09-29 |
1997-12-02 |
Emisphere Technologies, Inc. |
Diketopiperazine-based delivery systems
|
US5578323A
(en)
*
|
1992-06-15 |
1996-11-26 |
Emisphere Technologies, Inc. |
Proteinoid carriers and methods for preparation and use thereof
|
US5629020A
(en)
|
1994-04-22 |
1997-05-13 |
Emisphere Technologies, Inc. |
Modified amino acids for drug delivery
|
US5443841A
(en)
*
|
1992-06-15 |
1995-08-22 |
Emisphere Technologies, Inc. |
Proteinoid microspheres and methods for preparation and use thereof
|
US6221367B1
(en)
|
1992-06-15 |
2001-04-24 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5714167A
(en)
*
|
1992-06-15 |
1998-02-03 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US6331318B1
(en)
*
|
1994-09-30 |
2001-12-18 |
Emisphere Technologies Inc. |
Carbon-substituted diketopiperazine delivery systems
|
US5447728A
(en)
*
|
1992-06-15 |
1995-09-05 |
Emisphere Technologies, Inc. |
Desferrioxamine oral delivery system
|
US5451410A
(en)
*
|
1993-04-22 |
1995-09-19 |
Emisphere Technologies, Inc. |
Modified amino acids for encapsulating active agents
|
IL99699A
(en)
*
|
1990-10-10 |
2002-04-21 |
Autoimmune Inc |
Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
|
US6124267A
(en)
*
|
1991-02-05 |
2000-09-26 |
Southpac Trust Internationals, Inc. |
O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
|
US6309639B1
(en)
|
1991-02-05 |
2001-10-30 |
The Board Of Regents Of The University Of Oklahoma |
Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
|
IT1247472B
(it)
*
|
1991-05-31 |
1994-12-17 |
Fidia Spa |
Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
|
US6146850A
(en)
*
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
US5621083A
(en)
*
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
US5837491A
(en)
*
|
1991-11-04 |
1998-11-17 |
Xoma Corporation |
Polynucleotides encoding gelonin sequences
|
US5206219A
(en)
*
|
1991-11-25 |
1993-04-27 |
Applied Analytical Industries, Inc. |
Oral compositions of proteinaceous medicaments
|
US5766886A
(en)
*
|
1991-12-13 |
1998-06-16 |
Xoma Corporation |
Modified antibody variable domains
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US5160742A
(en)
*
|
1991-12-31 |
1992-11-03 |
Abbott Laboratories |
System for delivering an active substance for sustained release
|
US5352461A
(en)
*
|
1992-03-11 |
1994-10-04 |
Pharmaceutical Discovery Corporation |
Self assembling diketopiperazine drug delivery system
|
CA2136844A1
(en)
*
|
1992-05-28 |
1993-12-09 |
George A. Heavner |
Peptide inhibitors of selectin binding
|
JPH08504171A
(ja)
*
|
1992-05-28 |
1996-05-07 |
セントコー・インコーポレーテッド |
セレクチン結合のペプチド阻害剤
|
US6916489B2
(en)
*
|
1992-06-15 |
2005-07-12 |
Emisphere Technologies, Inc. |
Active agent transport systems
|
US5811127A
(en)
*
|
1992-06-15 |
1998-09-22 |
Emisphere Technologies, Inc. |
Desferrioxamine oral delivery system
|
US5792451A
(en)
*
|
1994-03-02 |
1998-08-11 |
Emisphere Technologies, Inc. |
Oral drug delivery compositions and methods
|
US5753617A
(en)
*
|
1992-09-08 |
1998-05-19 |
Centocor, Inc. |
Peptide inhibitors of cellular adhesion
|
WO1994005314A1
(en)
*
|
1992-09-08 |
1994-03-17 |
Centocor, Inc. |
Peptide inhibitors of leukocyte adhesion
|
WO1994007367A1
(en)
*
|
1992-09-29 |
1994-04-14 |
Apollon, Inc. |
Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
|
EP0646000A4
(en)
*
|
1992-11-16 |
1997-05-02 |
Univ Mercer |
COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
|
US5710123A
(en)
*
|
1992-12-18 |
1998-01-20 |
Centocor, Inc. |
Peptide inhibitors of selectin binding
|
US5401516A
(en)
*
|
1992-12-21 |
1995-03-28 |
Emisphere Technologies, Inc. |
Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US5981719A
(en)
|
1993-03-09 |
1999-11-09 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6610329B2
(en)
*
|
1993-04-22 |
2003-08-26 |
Emisphere Technologies Inc. |
Compositions for the delivery of antigens
|
US5958457A
(en)
*
|
1993-04-22 |
1999-09-28 |
Emisphere Technologies, Inc. |
Compositions for the delivery of antigens
|
DE69434418T2
(de)
*
|
1993-04-22 |
2005-12-22 |
Emisphere Technologies, Inc. |
Orale Dareichungsform
|
US5709861A
(en)
*
|
1993-04-22 |
1998-01-20 |
Emisphere Technologies, Inc. |
Compositions for the delivery of antigens
|
US20010003001A1
(en)
*
|
1993-04-22 |
2001-06-07 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5643957A
(en)
*
|
1993-04-22 |
1997-07-01 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
WO1994028878A1
(en)
*
|
1993-06-14 |
1994-12-22 |
Emisphere Technologies, Inc. |
Proteinoid carriers
|
WO1995014787A1
(en)
*
|
1993-11-22 |
1995-06-01 |
Centocor, Inc. |
Peptide inhibitors of selecting binding
|
ATE228832T1
(de)
*
|
1994-02-28 |
2002-12-15 |
Nanopharm Ag |
System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
|
JPH10503364A
(ja)
*
|
1994-05-10 |
1998-03-31 |
ザ ジェネラル ホスピタル コーポレーション |
C型肝炎ウイルスのアンチセンス阻害
|
US5962322A
(en)
*
|
1996-11-15 |
1999-10-05 |
Massachusetts Institute Of Technology |
Methods for modulation of cholesterol transport
|
US7078511B1
(en)
|
1994-06-23 |
2006-07-18 |
Massachusette Institute Of Technology |
Class BI and CI scavenger receptors
|
US5695993A
(en)
|
1994-08-12 |
1997-12-09 |
Oklahoma Medical Research Foundation |
Cloning and regulation of an endothelial cell protein C/activated protein C receptor
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US5898066A
(en)
*
|
1994-08-26 |
1999-04-27 |
Children's Medical Center Corporation |
Trophic factors for central nervous system regeneration
|
US5654273A
(en)
*
|
1994-09-22 |
1997-08-05 |
Children's Medical Center Corporation |
Synducin mediated modulation of tissue repair
|
US5858398A
(en)
*
|
1994-11-03 |
1999-01-12 |
Isomed Inc. |
Microparticular pharmaceutical compositions
|
US5866536A
(en)
*
|
1995-03-31 |
1999-02-02 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5989539A
(en)
*
|
1995-03-31 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6090958A
(en)
*
|
1995-03-31 |
2000-07-18 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5965121A
(en)
*
|
1995-03-31 |
1999-10-12 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
CN1151836C
(zh)
*
|
1995-03-31 |
2004-06-02 |
艾米斯菲尔技术有限公司 |
用作传送活性剂的化合物和组合物
|
US6001347A
(en)
|
1995-03-31 |
1999-12-14 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5820881A
(en)
*
|
1995-04-28 |
1998-10-13 |
Emisphere Technologies, Inc. |
Microspheres of diamide-dicarboxylic acids
|
US5759539A
(en)
*
|
1995-06-06 |
1998-06-02 |
Georgia Research Foundation, Inc. |
Method for rapid enzymatic alcohol removal
|
US6051258A
(en)
*
|
1995-06-07 |
2000-04-18 |
Emisphere Technologies, Inc. |
Proteinoid emulsions and methods for preparation and use thereof
|
US5667806A
(en)
*
|
1995-06-07 |
1997-09-16 |
Emisphere Technologies, Inc. |
Spray drying method and apparatus
|
US5861431A
(en)
*
|
1995-06-07 |
1999-01-19 |
Iotek, Inc. |
Incontinence treatment
|
US5750147A
(en)
|
1995-06-07 |
1998-05-12 |
Emisphere Technologies, Inc. |
Method of solubilizing and encapsulating itraconazole
|
US5824345A
(en)
*
|
1995-06-07 |
1998-10-20 |
Emisphere Technologies, Inc. |
Fragrances and flavorants
|
DE19681560T1
(de)
*
|
1995-09-11 |
1998-08-20 |
Emisphere Tech Inc |
Verfahren zur Herstellung von omega-Aminoalkansäure-Derivaten aus Cycloalkanonen
|
AU717113B2
(en)
†
|
1995-11-09 |
2000-03-16 |
Health Protection Agency |
Microencapsulated DNA for vaccination and gene therapy
|
US5843884A
(en)
*
|
1995-11-15 |
1998-12-01 |
Oklahoma Medical Research Foundation |
C9 complement inhibitor
|
US5925333A
(en)
*
|
1995-11-15 |
1999-07-20 |
Massachusetts Institute Of Technology |
Methods for modulation of lipid uptake
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
AU2595697A
(en)
*
|
1996-03-29 |
1997-10-22 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5888982A
(en)
*
|
1996-04-01 |
1999-03-30 |
President And Fellows Of Harvard College |
Regulation of vascular smooth muscle cell heme oxygenase-1
|
JP2000512671A
(ja)
|
1996-06-14 |
2000-09-26 |
エミスフェアー テクノロジーズ インク |
マイクロカプセル化香料及び調製方法
|
US5859227A
(en)
*
|
1996-07-31 |
1999-01-12 |
Bearsden Bio, Inc. |
RNA sequences which interact with RNA-binding proteins
|
US6004749A
(en)
*
|
1996-07-31 |
1999-12-21 |
Message Pharmaceuticals |
Method for identifying compounds affecting RNA/RNA binding protein interactions
|
US6107029A
(en)
*
|
1996-07-31 |
2000-08-22 |
Message Pharmaceticals, Inc. |
Universal method for detecting interactions between RNA molecules and RNA binding proteins
|
AU5243798A
(en)
|
1996-11-06 |
1998-05-29 |
Children's Medical Center Corporation |
Transgenic animal expressing a syndecan in the regions of hypothalamus
|
AU719629B2
(en)
|
1996-11-08 |
2000-05-11 |
Oklahoma Medical Research Foundation |
Endothelium specific expression regulated by EPCR control elements
|
US6391303B1
(en)
|
1996-11-18 |
2002-05-21 |
Emisphere Technologies, Inc. |
Methods and compositions for inducing oral tolerance in mammals
|
US5990166A
(en)
*
|
1997-02-07 |
1999-11-23 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5804688A
(en)
*
|
1997-02-07 |
1998-09-08 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6060513A
(en)
*
|
1997-02-07 |
2000-05-09 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5939381A
(en)
*
|
1997-02-07 |
1999-08-17 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US6358504B1
(en)
*
|
1997-02-07 |
2002-03-19 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5879681A
(en)
*
|
1997-02-07 |
1999-03-09 |
Emisphere Technolgies Inc. |
Compounds and compositions for delivering active agents
|
US5876710A
(en)
*
|
1997-02-07 |
1999-03-02 |
Emisphere Technologies Inc. |
Compounds and compositions for delivering active agents
|
DK0993831T3
(da)
|
1997-02-07 |
2008-03-25 |
Emisphere Tech Inc |
Forbindelser og præparater til tilförsel af aktive stoffer
|
US6313088B1
(en)
|
1997-02-07 |
2001-11-06 |
Emisphere Technologies, Inc. |
8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
|
US5863944A
(en)
*
|
1997-04-30 |
1999-01-26 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US5962710A
(en)
*
|
1997-05-09 |
1999-10-05 |
Emisphere Technologies, Inc. |
Method of preparing salicyloylamino acids
|
US20020099040A1
(en)
*
|
1997-09-05 |
2002-07-25 |
Monty Krieger |
Sr-bi antagonists and use thereof as contraceptives and in the treatment of steroidal overproduction
|
US7166568B1
(en)
|
1998-02-09 |
2007-01-23 |
Oklahoma Medical Research Foundation |
Compositions and methods to inhibit formation of the C5b-9 complex of complement
|
US6858706B2
(en)
|
1998-04-07 |
2005-02-22 |
St. Jude Children's Research Hospital |
Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
|
US6448224B1
(en)
|
1998-05-06 |
2002-09-10 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6331407B1
(en)
|
1998-05-06 |
2001-12-18 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6299875B1
(en)
|
1998-06-04 |
2001-10-09 |
Panacea Pharmaceuticals, Llc |
Methods to block IGE binding to cell surface receptors of mast cells
|
US6440929B1
(en)
|
1998-07-27 |
2002-08-27 |
Emisphere Technologies, Inc. |
Pulmonary delivery of active agents
|
DE69925276T2
(de)
|
1998-07-27 |
2005-10-06 |
Emisphere Technologies, Inc. |
Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
|
US6991798B1
(en)
|
1998-08-07 |
2006-01-31 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
DE69931930T2
(de)
|
1998-08-07 |
2006-10-05 |
Emisphere Technologies, Inc. |
Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
|
US6953568B1
(en)
|
1998-08-25 |
2005-10-11 |
Oklahoma Medical Research Foundation |
Targeting of molecules to large vessel endothelium using EPCR
|
US6921825B2
(en)
|
1998-09-16 |
2005-07-26 |
King Pharmaceuticuals Research & Development, Inc. |
Adenosine A3 receptor modulators
|
US6448253B1
(en)
|
1998-09-16 |
2002-09-10 |
King Pharmaceuticals Research And Development, Inc. |
Adenosine A3 receptor modulators
|
AU6294899A
(en)
|
1998-10-07 |
2000-04-26 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
DE19848002A1
(de)
|
1998-10-17 |
2000-04-20 |
Goldschmidt Ag Th |
Polypeptid-Polysiloxan-Copolymere
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
SI2319928T1
(sl)
*
|
1998-10-23 |
2013-08-30 |
Kirin-Amgen, Inc. |
Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
|
FR2786098B1
(fr)
|
1998-11-20 |
2003-05-30 |
Flamel Tech Sa |
Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
|
US6773911B1
(en)
*
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
NZ512581A
(en)
|
1999-01-08 |
2002-12-20 |
Univ Virginia Commonwealth |
Polymeric delivery agents comprising a polymer conjugated to a modified amino acid and derivatives thereof
|
CA2364849A1
(en)
|
1999-02-26 |
2000-08-31 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
AU5011400A
(en)
|
1999-05-14 |
2000-12-05 |
Arbor Vita Corporation |
Molecular interactions in t cells
|
JP2003501404A
(ja)
|
1999-06-04 |
2003-01-14 |
デルルックス ファーマシューティカル コーポレイション |
薬剤の脱水粒子からなる製剤およびこれの調製方法
|
US7361684B2
(en)
*
|
1999-06-28 |
2008-04-22 |
Massachusetts Institute Of Technology |
Screening of compounds for treatment of atherosclerosis and heart attack
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
US6908900B2
(en)
*
|
2001-01-17 |
2005-06-21 |
Zimmer & Associates Ag |
Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
|
US7671029B2
(en)
|
1999-08-06 |
2010-03-02 |
Immupharma Sa |
Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
|
ATE362374T1
(de)
*
|
1999-09-03 |
2007-06-15 |
Amgen Inc |
Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
|
DE60041978D1
(de)
|
1999-11-15 |
2009-05-20 |
Biocure Inc |
Auf äussere bedingungen ansprechende polymere hohle partikel
|
FR2801226B1
(fr)
|
1999-11-23 |
2002-01-25 |
Flamel Tech Sa |
Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
JP2003530870A
(ja)
|
2000-04-21 |
2003-10-21 |
アムジエン・インコーポレーテツド |
Apo−AI/AIIペプチド誘導体
|
US6667300B2
(en)
*
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US7030219B2
(en)
*
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
DE10026699A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
|
FR2814952B1
(fr)
|
2000-10-06 |
2004-01-02 |
Flamel Tech Sa |
Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6565888B1
(en)
|
2000-08-23 |
2003-05-20 |
Alkermes Controlled Therapeutics, Inc. |
Methods and compositions for the targeted delivery of biologically active agents
|
US8394813B2
(en)
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
US20030225300A1
(en)
*
|
2001-04-19 |
2003-12-04 |
Emisphere Technologies Inc. |
Compounds and compositions for delivering active agents
|
EP1921088B1
(en)
|
2001-05-11 |
2014-10-08 |
Amgen Inc. |
Peptides and related molecules that bind to tall-1
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
DE60232733D1
(de)
*
|
2001-08-30 |
2009-08-06 |
Sinai School Medicine |
Alternativ gesplicter zirkulierender gewebefaktor
|
WO2003020702A2
(en)
|
2001-08-31 |
2003-03-13 |
The Rockefeller University |
Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
|
WO2003020321A2
(en)
*
|
2001-09-06 |
2003-03-13 |
Zimmer Robert H |
Derivatives of pseudo-peptides, their preparation and their biological uses
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
PT2308888T
(pt)
|
2001-11-14 |
2017-05-03 |
Janssen Biotech Inc |
Anticorpos anti-il-6, composições, métodos e utilizações
|
US7056535B2
(en)
*
|
2001-12-20 |
2006-06-06 |
Kimberly-Clark Worldwide, Inc. |
Triggered release from proteinoid microspheres
|
US20030138975A1
(en)
*
|
2001-12-20 |
2003-07-24 |
Kimberly-Clark Worldwide, Inc. |
Diagnostic signal amplification with proteinoid microspheres
|
WO2003057165A2
(en)
|
2002-01-04 |
2003-07-17 |
The Rockefeller University |
COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
|
US7781396B2
(en)
*
|
2002-01-31 |
2010-08-24 |
Tel Aviv University Future Technology Development L.P. |
Peptides directed for diagnosis and treatment of amyloid-associated disease
|
US20040052928A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
US6939554B2
(en)
*
|
2002-02-05 |
2005-09-06 |
Michigan Biotechnology Institute |
Antimicrobial polymer
|
US7381399B2
(en)
|
2002-03-11 |
2008-06-03 |
Molecular Insight Pharmaceuticals, Inc. |
Technetium-dipyridine complexes, and methods of use thereof
|
DE60318938T2
(de)
|
2002-03-20 |
2009-01-22 |
Mannkind Corp., Valencia |
Inhalationsgerät
|
US20030180348A1
(en)
*
|
2002-03-22 |
2003-09-25 |
Levinson R. Saul |
Transcellular drug delivery system
|
US7906145B2
(en)
|
2002-04-09 |
2011-03-15 |
Flamel Technologies |
Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
|
FR2840614B1
(fr)
|
2002-06-07 |
2004-08-27 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
|
US7208467B2
(en)
|
2002-06-07 |
2007-04-24 |
Monty Krieger |
Lipid-altering compositions for the treatment of infertility
|
AU2003280130B2
(en)
|
2002-06-28 |
2009-06-11 |
Centocor, Inc. |
Mammalian CH1 deleted mimetibodies, compositions, methods and uses
|
WO2004007693A2
(en)
*
|
2002-07-16 |
2004-01-22 |
University Of South Florida |
Human immunosuppressive protein
|
PL376536A1
(pl)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
US20040171073A1
(en)
*
|
2002-10-08 |
2004-09-02 |
Massachusetts Institute Of Technology |
Compounds for modulation of cholesterol transport
|
US7491699B2
(en)
|
2002-12-09 |
2009-02-17 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures and methods of generating and using the same
|
EP2058275A1
(en)
*
|
2003-01-07 |
2009-05-13 |
Ramot at Tel-Aviv University Ltd. |
Peptide nanostructures encapsulating a foreign material and method of manufacturing same
|
CA2889013C
(en)
|
2003-03-07 |
2018-07-17 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
ZA200507757B
(en)
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
WO2004094457A2
(en)
*
|
2003-04-16 |
2004-11-04 |
Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University |
Stable rgd peptidomimetic composition
|
CN101052726A
(zh)
|
2003-05-09 |
2007-10-10 |
森托科尔公司 |
IL-23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
|
MXPA05012315A
(es)
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Compuestos poli(etilenglicol) modificados novedosos y usos de los mismos.
|
MXPA05012314A
(es)
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Radical separador para peptido modificado con polietilenglicol.
|
ES2354238T3
(es)
|
2003-07-03 |
2011-03-11 |
University Of Medicine And Dentistry Of New Jersey |
Genes como herramienta de diagnóstico para autismo.
|
US20050054614A1
(en)
*
|
2003-08-14 |
2005-03-10 |
Diacovo Thomas G. |
Methods of inhibiting leukocyte accumulation
|
US20050043239A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Jason Douangpanya |
Methods of inhibiting immune responses stimulated by an endogenous factor
|
EP1658273B1
(en)
*
|
2003-08-20 |
2007-01-03 |
Eli Lilly And Company |
Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
|
AU2004267044B8
(en)
*
|
2003-08-20 |
2009-12-17 |
Emisphere Technologies, Inc. |
Compounds, methods and formulations for the oral delivery of a glucagon like peptide (GLP)-1 compound or an melanocortin 4 receptor (MC4) agonist peptide
|
US20050233435A1
(en)
*
|
2003-09-04 |
2005-10-20 |
Nyu Medical Center |
Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
|
US8668926B1
(en)
|
2003-09-15 |
2014-03-11 |
Shaker A. Mousa |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
|
US8071134B2
(en)
*
|
2003-09-15 |
2011-12-06 |
Ordway Research Institute, Inc. |
Thyroid hormone analogs and methods of use
|
US9198887B2
(en)
|
2003-09-15 |
2015-12-01 |
Nanopharmaceuticals Llc |
Thyroid hormone analogs and methods of use
|
EP1670449B1
(en)
*
|
2003-09-15 |
2012-06-27 |
Ordway Research Institute, Inc. |
Thyroid hormone analogs and methods of use in angiogenesis
|
JP4917889B2
(ja)
*
|
2003-09-25 |
2012-04-18 |
テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. |
アミロイド関連疾患を処置するための組成物及びその使用方法
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
US7625707B2
(en)
*
|
2003-10-02 |
2009-12-01 |
Ramot At Tel Aviv University Ltd. |
Antibacterial agents and methods of identifying and utilizing same
|
EP3279328A1
(en)
|
2003-11-14 |
2018-02-07 |
Children's Medical Center Corporation |
Self-cleaving ribozymes and uses thereof
|
US20080119412A1
(en)
|
2003-12-23 |
2008-05-22 |
Nono Inc. |
Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins
|
PL2319500T3
(pl)
*
|
2004-03-12 |
2013-05-31 |
Biodel Inc |
Szybko działające kompozycje do dostarczania leku
|
KR20070004078A
(ko)
*
|
2004-03-31 |
2007-01-05 |
센토코 인코포레이티드 |
인간 glp-1 모방체, 조성물, 방법 및 용도
|
US7252446B2
(en)
*
|
2004-03-31 |
2007-08-07 |
Brother Kogoy Kabushiki Kaisha |
Image forming apparatus
|
CN101501211A
(zh)
|
2004-03-31 |
2009-08-05 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
US7514592B2
(en)
*
|
2004-04-05 |
2009-04-07 |
Massachusetts Institute Of Technology |
Inducible heart attack animal model
|
EP1761540B1
(en)
*
|
2004-05-13 |
2016-09-28 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
EP1755609A1
(en)
*
|
2004-05-25 |
2007-02-28 |
Icos Corporation |
Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
|
EP2380872B1
(en)
|
2004-06-15 |
2014-04-23 |
Cellceutix Corporation |
Polycationic compounds and uses thereof
|
JP2008505928A
(ja)
*
|
2004-07-08 |
2008-02-28 |
アムジェン インコーポレーテッド |
治療用ペプチド
|
US20090156471A1
(en)
*
|
2004-07-15 |
2009-06-18 |
Ramot At Tel Aviv University Ltd. |
Use of anti-amyloid agents for treating and typing pathogen infections
|
EP1781310B1
(en)
|
2004-08-02 |
2015-10-14 |
Ramot at Tel Aviv University Ltd. |
Articles of peptide nanostructures and method of forming the same
|
ATE539745T1
(de)
|
2004-08-19 |
2012-01-15 |
Univ Tel Aviv Future Tech Dev |
Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
|
ES2385934T3
(es)
|
2004-08-20 |
2012-08-03 |
Mannkind Corporation |
Catálisis de la síntesis de dicetopiperazina.
|
EP2314298B1
(en)
|
2004-08-23 |
2015-05-27 |
MannKind Corporation |
Microparticles comprising diketopiperazine salts for drug delivery
|
US7393662B2
(en)
*
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
US7786086B2
(en)
|
2004-09-08 |
2010-08-31 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
|
EP1797127B1
(en)
*
|
2004-09-24 |
2017-06-14 |
Amgen Inc. |
Modified fc molecules
|
CN1296098C
(zh)
*
|
2004-09-29 |
2007-01-24 |
薛南荣 |
口服胰岛素保护剂
|
WO2006042237A2
(en)
|
2004-10-06 |
2006-04-20 |
Mayo Foundation For Medical Education And Research |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
|
US20090005292A1
(en)
*
|
2004-11-11 |
2009-01-01 |
Affymax, Inc. |
Novel Peptides that Bind to the Erythropoietin Receptor
|
US7919093B2
(en)
|
2004-11-16 |
2011-04-05 |
Trustees Of Boston University |
Roles for dual endothelin-1/angiotensin II receptor (Dear) in hypertension and angiogenesis
|
US20090028889A1
(en)
|
2005-01-31 |
2009-01-29 |
Vaxinnate Corporation |
Novel Polypeptide Ligands For Toll-Like Receptor 2 (TLR2)
|
AU2006214190A1
(en)
*
|
2005-02-17 |
2006-08-24 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
US7919461B2
(en)
*
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
KR101600225B1
(ko)
|
2005-06-08 |
2016-03-04 |
다나-파버 캔서 인스티튜트 인크. |
예정 세포사 1(pd-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
|
WO2007005955A2
(en)
|
2005-06-30 |
2007-01-11 |
Centocor, Inc. |
Anti-il-23 antibodies, compositions, methods and uses
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
KR20160022404A
(ko)
|
2005-09-14 |
2016-02-29 |
맨카인드 코포레이션 |
활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
|
US20090022806A1
(en)
*
|
2006-12-22 |
2009-01-22 |
Mousa Shaker A |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
|
US9220788B2
(en)
*
|
2009-06-17 |
2015-12-29 |
Nanopharmaceuticals Llc |
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
|
US9498536B2
(en)
|
2005-09-15 |
2016-11-22 |
Nanopharmaceuticals Llc |
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
|
US10130686B2
(en)
|
2005-09-15 |
2018-11-20 |
Nanopharmaceuticals Llc |
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
|
US20100209382A1
(en)
*
|
2005-09-16 |
2010-08-19 |
Ordway Research Institute, Inc. |
Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
|
EP1973928A2
(en)
*
|
2005-10-11 |
2008-10-01 |
Ramot at Tel-Aviv University Ltd. |
Self-assembled fmoc-ff hydrogels
|
TW200732350A
(en)
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
US7879212B2
(en)
*
|
2005-11-03 |
2011-02-01 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructure-coated electrodes
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
EA035459B1
(ru)
|
2005-12-29 |
2020-06-19 |
Сентокор, Инк. |
Антитело против il-23p19
|
WO2007082154A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
US20070208074A1
(en)
*
|
2006-01-24 |
2007-09-06 |
Bonni Azad M |
Methods and compositions for treating and preventing tumors
|
US20090324574A1
(en)
|
2006-02-02 |
2009-12-31 |
Verenium Corporation |
Esterases and Related Nucleic Acids and Methods
|
MX2008010721A
(es)
|
2006-02-22 |
2008-09-01 |
Mannkind Corp |
Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
|
US7786090B2
(en)
*
|
2006-03-01 |
2010-08-31 |
President And Fellows Of Harvard College |
Methods and compositions for treating and preventing neurologic disorders
|
EP2007602A4
(en)
*
|
2006-03-31 |
2010-09-22 |
Centocor Ortho Biotech Inc |
HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
AU2007242061B2
(en)
|
2006-04-21 |
2012-11-29 |
Intervet International B.V. |
Pestivirus species
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
WO2007137163A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Georgia Tech Research Corporation |
Abc transporter ligand
|
US20080242608A1
(en)
*
|
2006-06-02 |
2008-10-02 |
Azad Bonni |
Methods and compositions for treating and preventing neurologic disorders
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
US7960606B2
(en)
*
|
2006-06-20 |
2011-06-14 |
The J. David Gladstone Institutes |
Mouse model of chronic heart failure and coronary atherosclerosis regression
|
WO2008002591A2
(en)
|
2006-06-26 |
2008-01-03 |
Amgen Inc |
Methods for treating atherosclerosis
|
US20100112600A1
(en)
*
|
2006-07-13 |
2010-05-06 |
Azard Bonni |
Methods and compositions for modulating synapse formation
|
US8324158B2
(en)
*
|
2006-07-14 |
2012-12-04 |
Georgia Tech Research Corporation |
Methods for inhibiting CLC-2 channel with GATX2
|
CA2667678A1
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
EP2078037A4
(en)
*
|
2006-11-10 |
2010-01-27 |
Dimerix Bioscience Pty Ltd |
HETERODIMERS / OLIGOMERS OF THE RECEPTOR FOR THE THYROTROPIN RELEASING HORMONE OF THE OREXIN RECEPTOR
|
EP2097422A4
(en)
*
|
2006-11-13 |
2010-04-14 |
Lilly Co Eli |
THIENOPYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND CARCINOMAS
|
UY30820A1
(es)
*
|
2006-12-21 |
2008-07-03 |
Centocor Inc |
Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
|
JP2010513526A
(ja)
*
|
2006-12-22 |
2010-04-30 |
シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド |
甲状腺ホルモン類縁体、拮抗剤および製剤のためのナノ粒子及び重合体製剤ならびにその使用
|
US8440185B2
(en)
*
|
2006-12-26 |
2013-05-14 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
CA2673659A1
(en)
*
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4
|
US20090142342A1
(en)
*
|
2006-12-27 |
2009-06-04 |
Johns Hopkins University |
B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
JP5623747B2
(ja)
|
2006-12-27 |
2014-11-12 |
エモリー ユニバーシティ |
感染症および腫瘍を処置するための組成物および方法
|
WO2008094275A1
(en)
|
2007-01-30 |
2008-08-07 |
New York University |
Peptides for treatment of conditions associated with nitric oxide
|
CA2687141C
(en)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
WO2008148023A2
(en)
*
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for treating neurological disorders
|
WO2009029342A2
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
NZ582794A
(en)
|
2007-07-26 |
2012-09-28 |
Amgen Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
WO2009033130A1
(en)
*
|
2007-09-07 |
2009-03-12 |
Gencia Corporation |
Mitochondrial compositions and uses thereof
|
JP2010540618A
(ja)
*
|
2007-10-02 |
2010-12-24 |
アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド |
幼児の成長および発達を増大するための内在性カンナビノイド
|
US8932558B2
(en)
*
|
2007-10-05 |
2015-01-13 |
Plaxgen Inc |
Multi-subunit biological complexes for treatment of plaque-associated diseases
|
WO2009058997A2
(en)
*
|
2007-11-01 |
2009-05-07 |
Biocept Inc. |
Non-invasive isolation of fetal nucleic acid
|
JP5352596B2
(ja)
*
|
2008-01-04 |
2013-11-27 |
バイオデル, インコーポレイテッド |
組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
|
BRPI0906797A2
(pt)
*
|
2008-01-09 |
2015-07-14 |
Molecular Insight Pharm Inc |
Inibidores de anidrase carbônica ix
|
WO2009111315A2
(en)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing granulomatous inflammation
|
WO2009140853A1
(en)
*
|
2008-05-23 |
2009-11-26 |
The University Of Hong Kong |
Combination therapy for the treatment of influenza
|
EP3281663B8
(en)
|
2008-06-13 |
2022-09-21 |
MannKind Corporation |
Breath powered dry powder inhaler for drug delivery
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
MX2010014240A
(es)
|
2008-06-20 |
2011-03-25 |
Mankind Corp |
Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
|
US20100008900A1
(en)
*
|
2008-07-14 |
2010-01-14 |
The University Of Hong Kong |
Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
|
TWI614024B
(zh)
|
2008-08-11 |
2018-02-11 |
曼凱公司 |
超快起作用胰島素之用途
|
CA2733642A1
(en)
|
2008-08-14 |
2010-02-18 |
Cephalon Australia Pty Ltd |
Anti-il-12/il-23 antibodies
|
JP2012500197A
(ja)
|
2008-08-15 |
2012-01-05 |
ジョージタウン ユニバーシティー |
Rassf1a発現およびヒト癌細胞増殖の蛍光調節剤
|
CN102149705B
(zh)
|
2008-08-22 |
2013-08-07 |
赛诺菲-安万特 |
作为肥大细胞类胰蛋白酶抑制剂的[4-(5-氨基甲基-2-氟苯基)-哌啶-1-基]-[7-氟-1-(2-甲氧基乙基)-4-三氟甲氧基-1h-吲哚-3-基]-甲酮
|
EP2328919A2
(en)
*
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
US8198062B2
(en)
*
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
JP2012505238A
(ja)
|
2008-10-08 |
2012-03-01 |
カイフィア ファーマシューティカルズ, インコーポレイテッド |
Gabaコンジュゲートおよびそれらの使用方法
|
WO2010046778A2
(en)
*
|
2008-10-21 |
2010-04-29 |
International Vaccine Institute |
Novel shigella frotein antigens and methods
|
KR101781907B1
(ko)
|
2008-10-31 |
2017-09-26 |
얀센 바이오테크 인코포레이티드 |
파이브로넥틴 타입 ⅲ 도메인 기반 스캐폴드 조성물, 방법 및 용도
|
CA3092449A1
(en)
|
2008-11-13 |
2010-05-20 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
WO2010065899A2
(en)
|
2008-12-05 |
2010-06-10 |
Molecular Insight Pharmaceuticals, Inc. |
Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof
|
EP2373622A2
(en)
*
|
2008-12-05 |
2011-10-12 |
Molecular Insight Pharmaceuticals, Inc. |
Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
|
WO2010065906A2
(en)
|
2008-12-05 |
2010-06-10 |
Molecular Insight Pharmaceuticals, Inc. |
Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
|
US8628762B2
(en)
|
2008-12-10 |
2014-01-14 |
Icahn School Of Medicine At Mount Sinai |
T-helper cell type 17 lineage-specific adjuvants, compositions and methods
|
AR074776A1
(es)
|
2008-12-18 |
2011-02-09 |
Sanofi Aventis |
Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
|
WO2010075332A1
(en)
|
2008-12-23 |
2010-07-01 |
Charitable Leadership Foundation |
Small molecule ligands of the integrin rgd recognition site and methods of use
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
EP2396011B1
(en)
|
2009-02-12 |
2016-04-13 |
Janssen Biotech, Inc. |
Fibronectin type iii domain based scaffold compositions, methods and uses
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
CA2754595C
(en)
|
2009-03-11 |
2017-06-27 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
MX2011009955A
(es)
|
2009-03-24 |
2011-11-18 |
Gilead Calistoga Llc |
Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso.
|
WO2010120506A1
(en)
*
|
2009-03-31 |
2010-10-21 |
Ordway Research Institute, Inc. |
Combination treatment of cancer with cetuximab and tetrac
|
CN102458410A
(zh)
*
|
2009-04-20 |
2012-05-16 |
吉联亚·卡利斯托加有限责任公司 |
治疗实体瘤的方法
|
US20110038852A1
(en)
*
|
2009-06-10 |
2011-02-17 |
3-V Biosciences, Inc. |
Antivirals that target transporters, carriers, and ion channels
|
US8551528B2
(en)
|
2009-06-12 |
2013-10-08 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
WO2010147965A2
(en)
|
2009-06-15 |
2010-12-23 |
Molecular Insight Pharmaceuticals, Inc. |
Process for production of heterodimers of glutamic acid
|
MX2012000817A
(es)
|
2009-07-21 |
2012-05-08 |
Gilead Calistoga Llc |
Tratamiento para desordenes del higado con inhibidores pi3k.
|
FR2955324A1
(fr)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
|
AU2010286361A1
(en)
|
2009-08-31 |
2012-03-15 |
Amplimmune, Inc. |
Methods and compositions for the inhibition of transplant rejection
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
EP2493468A1
(en)
|
2009-10-30 |
2012-09-05 |
Sanofi |
Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
|
EP2496295A1
(en)
|
2009-11-03 |
2012-09-12 |
MannKind Corporation |
An apparatus and method for simulating inhalation efforts
|
MY173795A
(en)
|
2009-11-05 |
2020-02-24 |
Incozen Therapeutics Pvt Ltd |
Novel benzopyran kinase modulators
|
CA2780875A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
CA2780678A1
(en)
|
2009-11-19 |
2011-05-26 |
Ou Solis Biodyne |
Compositions for increasing polypeptide stability and activity, and related methods
|
SG181501A1
(en)
|
2009-12-23 |
2012-07-30 |
Sanofi Sa |
Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
|
KR20120112600A
(ko)
|
2009-12-23 |
2012-10-11 |
사노피 |
[4[4?(5?아미노메틸?2?플루오로?페닐)?피페리딘?1?일]?(1h?피롤로?피리딘?일)?메탄온들 및 이들의 합성
|
WO2011094430A2
(en)
|
2010-01-27 |
2011-08-04 |
Children's Medical Center Corporation |
Pro-angiogenic fragments of prominin-1 and uses thereof
|
KR101878369B1
(ko)
|
2010-03-22 |
2018-07-16 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
JP2013525484A
(ja)
|
2010-05-03 |
2013-06-20 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
|
EA025281B9
(ru)
|
2010-05-17 |
2017-08-31 |
Инкозен Терапьютикс Пвт. Лтд. |
СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
|
EP4269563A3
(en)
|
2010-06-19 |
2024-01-10 |
Memorial Sloan-Kettering Cancer Center |
Anti-gd2 antibodies
|
BR112012033060A2
(pt)
|
2010-06-21 |
2018-02-27 |
Mannkind Corp |
métodos de sistema de liberação de fármaco em pó seco
|
MY161390A
(en)
|
2010-06-24 |
2017-04-14 |
Genentech Inc |
Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
|
US8862410B2
(en)
|
2010-08-02 |
2014-10-14 |
Population Diagnostics, Inc. |
Compositions and methods for discovery of causative mutations in genetic disorders
|
US20120087985A1
(en)
*
|
2010-10-07 |
2012-04-12 |
Biodel Inc. |
Small peptide sequences for stabilizing biomolecules
|
CN102462837B
(zh)
*
|
2010-11-19 |
2016-08-03 |
生物林格斯Ip有限公司 |
抗炎组合物
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
US8802240B2
(en)
|
2011-01-06 |
2014-08-12 |
Nanopharmaceuticals Llc |
Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
|
CA2821985C
(en)
|
2011-01-11 |
2019-07-09 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
US20140031383A1
(en)
|
2011-02-08 |
2014-01-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for treatment of melanoma
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
AU2012225390B2
(en)
|
2011-03-08 |
2015-11-12 |
Sagimet Biosciences Inc. |
Heterocyclic modulators of lipid synthesis
|
AU2012228990B2
(en)
|
2011-03-16 |
2017-04-06 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.3 and Nav1.7
|
WO2012134975A1
(en)
|
2011-03-28 |
2012-10-04 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
WO2012130193A1
(en)
|
2011-03-31 |
2012-10-04 |
Zentiva, K.S. |
Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
|
KR101940832B1
(ko)
|
2011-04-01 |
2019-01-21 |
맨카인드 코포레이션 |
의약 카트리지용 블리스터 패키지
|
SI2705029T1
(sl)
|
2011-05-04 |
2019-03-29 |
Rhizen Pharmaceuticals S.A. |
Nove spojine kot modulatori protein-kinaz
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
DK2751279T3
(da)
|
2011-08-31 |
2017-11-20 |
St Jude Children's Res Hospital |
Fremgangsmåder og sammensætninger til påvisning af niveauet af lysosomal exocytose-aktivitet og fremgangsmåder til anvendelse
|
AU2012312654B2
(en)
|
2011-09-19 |
2017-04-13 |
Gencia Corporation |
Modified creatine compounds
|
DK2766483T3
(da)
|
2011-10-10 |
2022-04-19 |
Hospital For Sick Children |
Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser
|
EP2776053A1
(en)
|
2011-10-24 |
2014-09-17 |
MannKind Corporation |
Methods and compositions for treating pain
|
CN104039826A
(zh)
|
2011-10-31 |
2014-09-10 |
弗·哈夫曼-拉罗切有限公司 |
抗体制剂
|
EP2773779B1
(en)
|
2011-11-04 |
2020-10-14 |
Population Bio, Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
AU2013207486A1
(en)
|
2012-01-06 |
2014-08-21 |
Molecular Insight Pharmaceuticals |
Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
|
DK2812452T3
(da)
|
2012-02-09 |
2020-06-29 |
Population Bio Inc |
Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser
|
WO2013130773A2
(en)
|
2012-02-29 |
2013-09-06 |
Ethicon Endo-Surgery, Inc. |
Compositions of microbiota and methods related thereto
|
AU2013203620B2
(en)
|
2012-03-05 |
2015-11-19 |
Gilead Calistoga Llc |
Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
JP6192708B2
(ja)
|
2012-03-30 |
2017-09-06 |
ライゼン・ファーマシューティカルズ・エスアー |
C−metプロテインキナーゼ調節物質としての新規3,5−二置換−3h−イミダゾ[4,5−b]ピリジン化合物および3,5−二置換−3h−[1,2,3]トリアゾロ[4,5−b]ピリジン化合物
|
JP2015516400A
(ja)
|
2012-04-24 |
2015-06-11 |
ユニバーシティー オブ マイアミUniversity Of Miami |
侵襲的かつ多剤耐性の病原体に対するパーフォリン2の防御
|
EP2662079A1
(en)
|
2012-05-10 |
2013-11-13 |
Ordway Research Institute, Inc. |
Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
|
SG11201500218VA
(en)
|
2012-07-12 |
2015-03-30 |
Mannkind Corp |
Dry powder drug delivery systems and methods
|
EP2895621B1
(en)
|
2012-09-14 |
2020-10-21 |
Population Bio, Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
EP2900835A4
(en)
|
2012-09-27 |
2016-05-11 |
Population Diagnotics Inc |
METHODS AND COMPOSITIONS FOR DETECTING AND TREATING DEVELOPMENTAL DISORDERS
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
EP2935311B1
(en)
|
2012-12-20 |
2021-03-31 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
HUE044552T2
(hu)
|
2013-01-14 |
2019-11-28 |
Molecular Insight Pharm Inc |
Triazinalapú radiogyógyszerek és radiológiai képalkotó ágensek
|
US20140255403A1
(en)
|
2013-03-06 |
2014-09-11 |
Hadasit Medical Research Services & Development Ltd. |
Oral composition comprising a tnf antagonist and use thereof
|
UY35397A
(es)
|
2013-03-12 |
2014-10-31 |
Amgen Inc |
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
EP3587404B1
(en)
|
2013-03-15 |
2022-07-13 |
MannKind Corporation |
Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
|
RU2015143130A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженсиа Корпорейшен |
Композиции и способы лечения состояний, поражающих эпидермис
|
CA2904685C
(en)
|
2013-03-15 |
2022-05-03 |
John J. Freeman |
Formation of n-protected bis-3,6-(4-aminobutyl)-2,5-diketopiperazine through a cyclic .alpha.-n-protected active amino ester intermediate
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗gd2抗体
|
JP6462663B2
(ja)
|
2013-04-12 |
2019-01-30 |
アイカーン スクール オブ メディシン アット マウント シナイ |
心的外傷後ストレス障害を処置するための方法
|
BR122019026637B1
(pt)
|
2013-07-18 |
2023-09-26 |
Mannkind Corporation |
Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
|
GB2535034A
(en)
|
2013-07-21 |
2016-08-10 |
Whole Biome Inc |
Methods and systems for microbiome characterization, monitoring and treatment
|
CA2920488C
(en)
|
2013-08-05 |
2022-04-26 |
Mannkind Corporation |
Insufflation apparatus and methods
|
PL3041958T3
(pl)
|
2013-09-04 |
2020-11-02 |
Cold Spring Harbor Laboratory |
Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
|
US10259875B2
(en)
|
2013-10-01 |
2019-04-16 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of BIM
|
WO2015074050A1
(en)
|
2013-11-18 |
2015-05-21 |
Nanopharmaceuticals Llc |
Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
|
JP2017500319A
(ja)
|
2013-12-20 |
2017-01-05 |
ギリアード カリストガ エルエルシー |
(s)−2−(1−(9h−プリン−6−イルアミノ)プロピル)−5−フルオロ−3−フェニルキナゾリン−4(3h)−オンの塩酸塩の多形形態
|
JP6820097B2
(ja)
|
2013-12-20 |
2021-01-27 |
サギメット バイオサイエンシーズ インコーポレイテッド |
脂質合成の複素環式モジュレータ及びその組み合わせ
|
PL3083630T3
(pl)
|
2013-12-20 |
2020-02-28 |
Gilead Calistoga Llc |
Sposoby otrzymywania inhibitorów 3-kinazy fosfatydyloinozytolu
|
MX2016008841A
(es)
|
2014-01-07 |
2016-10-13 |
3-V Biosciences Inc |
Moduladores heterociclicos de la sintesis de lipidos para su uso contra el cancer e infecciones virales.
|
US10293035B2
(en)
|
2014-03-28 |
2019-05-21 |
University Of Washington Through Its Center For Commercialization |
Breast and ovarian cancer vaccines
|
WO2015148905A1
(en)
|
2014-03-28 |
2015-10-01 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
ES2950789T3
(es)
|
2014-06-10 |
2023-10-13 |
Amgen Inc |
Polipéptidos de apelina
|
NZ726360A
(en)
|
2014-06-13 |
2018-04-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
WO2016014148A1
(en)
|
2014-07-23 |
2016-01-28 |
Mayo Foundation For Medical Education And Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
CA2996445A1
(en)
|
2014-09-05 |
2016-03-10 |
Eli Hatchwell |
Methods and compositions for inhibiting and treating neurological conditions
|
WO2016054240A1
(en)
|
2014-09-30 |
2016-04-07 |
Sean Dalziel |
Fixed dose combinations for the treatment of viral diseases
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
CN113730442A
(zh)
|
2014-10-31 |
2021-12-03 |
潘德勒姆治疗公司 |
与病症的微生物治疗和诊断有关的方法和组合物
|
IL296062A
(en)
|
2015-03-17 |
2022-10-01 |
Memorial Sloan Kettering Cancer Center |
Antibodies against muc16 and their uses
|
JP6758314B2
(ja)
|
2015-03-19 |
2020-09-23 |
サギメット バイオサイエンシーズ インコーポレイテッド |
脂質合成の複素環式調節因子
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
US10548844B2
(en)
|
2015-12-14 |
2020-02-04 |
Massachusetts Institute Of Technology |
pH-responsive mucoadhesive polymeric encapsulated microorganisms
|
US10973748B2
(en)
|
2016-04-21 |
2021-04-13 |
Versitech Limited |
Compositions and methods for lightening skin and reducing hyperpigmentation
|
AU2017259821A1
(en)
|
2016-05-04 |
2018-12-13 |
Abilita Bio, Inc. |
Methods and platform for preparing multispanning membrane proteins
|
CN109715551A
(zh)
|
2016-06-07 |
2019-05-03 |
纳米药业有限责任公司 |
与αvβ3整联蛋白甲状腺拮抗剂缀合的不可裂解聚合物
|
WO2018014038A1
(en)
|
2016-07-15 |
2018-01-18 |
Poseida Therapeutics, Inc. |
Chimeric antigen receptors and methods for use
|
CN109715670A
(zh)
|
2016-07-15 |
2019-05-03 |
波赛达治疗公司 |
对muc1特异性的嵌合抗原受体(car)及其使用方法
|
CA3051484A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
CN110234351A
(zh)
|
2017-01-30 |
2019-09-13 |
詹森生物科技公司 |
用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
US11318190B2
(en)
|
2017-05-05 |
2022-05-03 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating liver disease
|
CA3073838A1
(en)
|
2017-08-30 |
2019-03-07 |
Pendulum Therapeutics, Inc. |
Methods and compositions for treatment of microbiome-associated disorders
|
CA3079141A1
(en)
|
2017-10-17 |
2019-04-25 |
Rhizen Pharmaceuticals Sa |
Crac channel modulators for treating esophageal cancer
|
WO2019082124A1
(en)
|
2017-10-26 |
2019-05-02 |
Rhizen Pharmaceuticals Sa |
COMPOSITION AND METHOD FOR THE TREATMENT OF LARGE B-CELL DIFFUSED LYMPHOMA
|
KR20200079256A
(ko)
|
2017-10-30 |
2020-07-02 |
리젠 파마슈티컬스 소시에떼 아노님 |
혈액암 및 고형암을 치료하기 위한 칼슘 방출-활성화된 칼슘 채널 조절제
|
EA202091082A1
(ru)
|
2017-12-06 |
2020-10-23 |
Ризен Фармасьютикалз Са |
Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы
|
AU2018393110B2
(en)
|
2017-12-20 |
2023-04-27 |
Poseida Therapeutics, Inc. |
VCAR compositions and methods for use
|
US11351137B2
(en)
|
2018-04-11 |
2022-06-07 |
Nanopharmaceuticals Llc |
Composition and method for dual targeting in treatment of neuroendocrine tumors
|
US10328043B1
(en)
|
2018-04-11 |
2019-06-25 |
Nanopharmaceuticals, Llc. |
Composition and method for dual targeting in treatment of neuroendocrine tumors
|
EP3790587A4
(en)
|
2018-05-11 |
2022-01-26 |
Janssen Biotech, Inc. |
METHOD OF TREATMENT OF DEPRESSION USING IL-23 ANTIBODIES
|
EP3814492A4
(en)
|
2018-06-29 |
2022-02-23 |
Wuhan Neurophth Biotechnology Limited Company |
COMPOSITIONS AND METHODS OF TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY
|
WO2020001657A1
(en)
|
2018-06-29 |
2020-01-02 |
Wuhan Neurophth Biological Technology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
WO2020023507A1
(en)
*
|
2018-07-23 |
2020-01-30 |
Cornell University |
Natural fluorescent polyhedral amino acid crystals for efficient entrapment and systemic delivery of hydrophobic small molecules
|
EP3625368B8
(en)
|
2018-08-08 |
2022-12-14 |
PML Screening, LLC |
Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
|
SG11202101032VA
(en)
|
2018-08-20 |
2021-02-25 |
Wuhan Neurophth Biotechnology Ltd Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
EP3856206A1
(en)
|
2018-09-27 |
2021-08-04 |
Phosphogam, Inc. |
Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
|
US20220042038A1
(en)
|
2018-12-20 |
2022-02-10 |
Poseida Therapeutics, Inc. |
Nanotransposon compositions and methods of use
|
CA3126654A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
MX2021008871A
(es)
|
2019-01-23 |
2021-08-19 |
Janssen Biotech Inc |
Composiciones de anticuerpos anti-tnf para usarse en metodos para el tratamiento de la artritis psoriasica.
|
JP2022525179A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための産生方法
|
EP3938391A1
(en)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Methods for producing anti-tnf antibody compositions
|
US20220153829A1
(en)
|
2019-03-14 |
2022-05-19 |
Janssen Biotech, Inc. |
Methods for Producing Anti-TNF Antibody Compositions
|
TW202102266A
(zh)
|
2019-04-01 |
2021-01-16 |
美商建南德克公司 |
用於穩定含有蛋白質之配方之組合物及方法
|
BR112021023295A2
(pt)
|
2019-05-23 |
2022-02-08 |
Janssen Biotech Inc |
Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
|
WO2020245676A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
|
KR20220030952A
(ko)
|
2019-06-03 |
2022-03-11 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
KR20220057596A
(ko)
|
2019-09-05 |
2022-05-09 |
포세이다 테라퓨틱스, 인크. |
동종이계 세포 조성물 및 사용 방법
|
CN114828842A
(zh)
|
2019-10-21 |
2022-07-29 |
理森制药股份公司 |
用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
|
CN113025633A
(zh)
|
2019-12-09 |
2021-06-25 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
WO2021127505A1
(en)
|
2019-12-20 |
2021-06-24 |
Poseida Therapeutics, Inc. |
Anti-muc1 compositions and methods of use
|
KR20220149588A
(ko)
|
2020-03-04 |
2022-11-08 |
포세이다 테라퓨틱스, 인크. |
대사성 간 장애의 치료를 위한 조성물 및 방법
|
EP4118107A1
(en)
|
2020-03-11 |
2023-01-18 |
Poseida Therapeutics, Inc. |
Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
|
CA3174777A1
(en)
|
2020-04-14 |
2021-10-21 |
Eric M. Ostertag |
Compositions and methods for use in the treatment of cancer
|
WO2021214588A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating coronavirus infections
|
WO2021214587A1
(en)
|
2020-04-21 |
2021-10-28 |
Janssen Biotech, Inc. |
Anti-tnf alpha agent for treating viral infections
|
US10961204B1
(en)
|
2020-04-29 |
2021-03-30 |
Nanopharmaceuticals Llc |
Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
|
WO2022182797A1
(en)
|
2021-02-23 |
2022-09-01 |
Poseida Therapeutics, Inc. |
Genetically modified induced pluripotent stem cells and methods of use thereof
|
WO2022187671A1
(en)
|
2021-03-04 |
2022-09-09 |
Poseida Therapeutics, Inc. |
Compositions and methods for the treatment of hemophilia
|
WO2023280157A1
(zh)
|
2021-07-05 |
2023-01-12 |
武汉纽福斯生物科技有限公司 |
一种抗vegf抗体体内表达系统的构建和应用
|
US20230040065A1
(en)
|
2021-07-09 |
2023-02-09 |
Janssen Biotech, Inc. |
Manufacturing Methods for Producing Anti-TNF Antibody Compositions
|
CN117957251A
(zh)
|
2021-07-09 |
2024-04-30 |
詹森生物科技公司 |
用于制备抗tnf抗体组合物的制造方法
|
US20230048743A1
(en)
|
2021-07-12 |
2023-02-16 |
Genentech Inc. |
Structures for Reducing Antibody-Lipase Binding
|
CA3228344A1
(en)
|
2021-08-06 |
2023-02-09 |
Wuhan Neurophth Biotechnology Limited Company |
Composition and method for treating leber's hereditary optic neuropathy caused by nd4 mutation
|
WO2023017537A1
(en)
|
2021-08-12 |
2023-02-16 |
Celagenex Research (India) Pvt. Ltd. |
Oral algal oil based gastro-intestinal tract permeable peptide composition
|
AU2022360244A1
(en)
|
2021-10-04 |
2024-04-11 |
Poseida Therapeutics, Inc. |
Transposon compositions and methods of use thereof
|
US11723888B2
(en)
|
2021-12-09 |
2023-08-15 |
Nanopharmaceuticals Llc |
Polymer conjugated thyrointegrin antagonists
|
WO2023164573A1
(en)
|
2022-02-23 |
2023-08-31 |
Poseida Therapeutics, Inc. |
Genetically modified cells and methods of use thereof
|
WO2024036273A1
(en)
|
2022-08-11 |
2024-02-15 |
Poseida Therapeutics, Inc. |
Chimeric cd8-alpha co-receptor compositions and methods of use
|